使用老年营养风险指数,C反应蛋白和疾病状况的新型评分系统预测了第二次异构干细胞移植后的生存率
Yasutaka Sadaga1, Yuho Najima1, Takayoshi Tachibana2
1Hematology Division, Tokyo Metropolitan Cancer and Infectious Diseases Center, Komagome Hospital, Bunkyo-Ku, Tokyo, Japan.
Transplantation and cellular therapy
|December 6, 2025
概括
老年营养风险指数 (GNRI) 是第二次全源干细胞移植 (SCT2) 患者结果的关键预测指标. 使用GNRI,疾病状态和CRP水平的新评分系统改善了风险分层,以获得更好的治疗策略.
科学领域:
- 血液学 血液学 血液学
- 在瘤学瘤学.
- 老年病的医生 老年病的医生
- 营养 营养 营养 营养 营养
背景情况:
- 第二次全基性干细胞移植 (SCT2) 为复发性血液性恶性瘤提供治疗潜力,但历史上结果不佳.
- 确定可靠的预后因素对于改善SCT2.2后的患者管理和生存率至关重要.
研究的目的:
- 验证老年营养风险指数 (GNRI) 作为SCT2结果的预后因素.
- 开发和验证一种新的评分系统,用于使用GNRI,疾病状态和C反应蛋白 (CRP) 水平预测SCT2结果.
主要方法:
- 在2004年至2020年期间接受SCT2的376名患者的多中心回顾性分析.
- 多变量分析以确定总生存时间 (OS) 的独立预后因素.
- 开发和验证一个风险分层评分系统.
主要成果:
- 确定了GNRI,疾病状态和CRP水平作为OS的独立预后因素.
- 高GNRI (≥92.0) 的患者显示显著改善3年生存率 (36.0%对14.3%) 和较低的非复发死亡率 (27.2%对50.9%).
- 新的评分系统将患者分为低风险,中风险和高风险组,分别具有明显的3年OS率 (50.7%,29.5%和11.1%).
结论:
- 根据GNRI的评估,营养状况对SCT2结果产生重大影响.
- 开发的评分系统为SCT2的风险分类和优化治疗策略提供了一个实用的工具.
- 需要进一步的研究来评估基于这种风险分层方法的干预措施.
更多相关视频
09:00High Throughput Sequential ELISA for Validation of Biomarkers of Acute Graft-Versus-Host Disease
Published on: October 31, 2012
16.2K
07:13Comparison of Predictive Performance of Three Lymph Node Staging Systems in Colorectal Signet Ring Cell Carcinoma Based on Machine Learning Model
Published on: April 18, 2025
472
相关概念视频
Cancer Survival Analysis
630
Cancer survival analysis focuses on quantifying and interpreting the time from a key starting point, such as diagnosis or the initiation of treatment, to a specific endpoint, such as remission or death. This analysis provides critical insights into treatment effectiveness and factors that influence patient outcomes, helping to shape clinical decisions and guide prognostic evaluations. A cornerstone of oncology research, survival analysis tackles the challenges of skewed, non-normally...
630
Bone Marrow Sampling and Transplants
829
Bone marrow transplant is a potential cure for several diseases, including cancer and specific genetic disorders. Notably, this procedure is applicable for patients suffering from aplastic anemia, certain types of leukemia, severe combined immunodeficiency disease (SCID), Hodgkin's disease, non-Hodgkin's lymphoma, multiple myeloma, thalassemia, sickle-cell disease, and certain cancers.
The transplant begins with high doses of chemotherapy and radiation treatment, which aim to destroy...
The transplant begins with high doses of chemotherapy and radiation treatment, which aim to destroy...
829
